Xeris Pharmaceuticals (XERS.Q) announces today that the U.S. Food and Drug Administration (FDA) has allowed the Investigational New Drug Application (IND) for the Company’s XeriSol™ levothyroxine (XP-8121) for hypothyroidism…
Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property